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Abstract
Background: In the United Kingdom, 350,000 patients per year are referred to hospital clinics with suspicious moles, and
approximately half undergo a biopsy to identify the 5%-10% who require further treatment. If cancer cannot be ruled out clinically
and on the basis of biopsy results, the lesion is surgically removed. One type of precancerous mole, called lentigo maligna, is
particularly challenging to delineate and treat. Reflectance confocal microscopy (VivaScope, Caliber Imaging & Diagnostics) is
an imaging technique that can supplement dermoscopy in identifying whether a clinically suspicious mole is malignant and can
better assess lentigo maligna margins for excision. It allows clinicians to visualize the skin lesion to a depth of 200 microns with
subcellular resolution, described as quasi-histological, and therefore better guide more accurate diagnoses.
Objective: The aim of this paper is to describe a prospective, single blinded, multicenter study to examine patients with clinically
suspicious moles or lentigo maligna to determine whether confocal microscopy can both reduce the number of unnecessary
biopsies of moles and more accurately guide the surgical excision margins of lentigo maligna.
Methods: This study will prospectively recruit adults into the following two cohorts: diagnostic accuracy and margin delineation.
The diagnostic accuracy cohort will assess people with clinically suspicious lesions suspected of being diagnosed with melanoma
and having an equivocal finding on dermoscopy or persistent clinical suspicion despite normal dermoscopy. Diagnostic accuracy
will include the sensitivity and specificity of VivaScope in comparison with the histological diagnosis as the gold standard for
patients. The margin delineation cohort will assess the ability of VivaScope to accurately delineate the margins of lentigo maligna
compared with that of dermoscopy alone using margins taken during Mohs micrographic surgery as the gold standard. The primary
study outcomes will be the diagnostic accuracy of VivaScope for the first cohort of patients and margin agreement between
VivaScope and the final pathology report for the second cohort of patients.
Results: Funding for this proposed research is being secured.
Conclusions: The outcomes of the proposed study will indicate how many biopsies of nonmelanoma lesions, which are potentially
unnecessary, could be prevented. This would reduce patient anxiety and cost to the National Health Service (NHS) in the United
Kingdom. Improved margin delineation of lentigo maligna could also improve the surgical clearance rates and decrease overall
cost. The results would demonstrate whether the adoption of VivaScope would potentially benefit patients and the NHS.
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Introduction
Background
In the United Kingdom, 350,000 patients per year are referred
to hospitals with suspicious moles, and approximately half
undergo a biopsy to identify the 5%-10% who require further
treatment [1]. Typically, a dermatologist diagnoses skin cancer
based on clinical history and examination that is aided by a
dermatoscope. If cancer cannot be ruled out, the lesion is
surgically removed or in some cases, it is monitored by repeated
visits to the clinic. Lentigo maligna (LM), a premalignant lesion
that grows slowly on sun-exposed sites and can transform into
a melanoma, is particularly challenging to treat. Because it is
difficult to identify the transformation of LM into a melanoma,
it is usually treated when it is found, before malignant
transformation. Its margins are difficult to assess in a visual
examination with or without the aid of a dermatoscope. The
consequence of this uncertainty is that despite surgery with a 5
mm margin around the clinical edge, the treatment has high
rates of incomplete excisions and recurrence rates are high [2].
Reflectance confocal microscopy (RCM) is a noninvasive
real-time imaging technique used at the bedside. The VivaScope
1500 and 3000 (Caliber Imaging & Diagnostics) use
near-infrared point-laser light to image the top layers of the
skin, blood vessels, and pigment with a cellular resolution [3].
The technology can help identify whether a clinically suspicious
mole is histologically suspicious and needs to be removed. It
can also guide visualization of the true margins of LM prior to
surgical removal. In these cases (as in this study), Mohs surgery
can be used, which involves examination of the entirety of the
surgical margins in multiple stages to ensure that the whole
tumor is removed.
In 2015, the National Institute for Health and Care Excellence
(NICE) Diagnostics Assessment Programme published
Diagnostics Guidance 19 (DG19) [3], which examined the use
of VivaScope and its potential role in the National Health
Service (NHS). DG19 stated that there was insufficient evidence
to recommend the routine adoption of VivaScope in the NHS
for the assessment of skin cancer. The guidance identified a
number of studies that have shown that VivaScope can improve
the specificity of melanoma diagnosis when used as an adjunct
to dermoscopy [3].
VivaScope examination in patients with difficult-to-diagnose
moles has been shown to have higher specificity than
dermoscopy [4]. This can potentially reduce unnecessary
biopsies by enabling a more accurate clinical diagnosis.
VivaScope can also more accurately define the edges of LM in
comparison with dermoscopy [5]. This is particularly important
because these lesions occur on the face in the elderly and are
often large, requiring complex reconstructive surgery. A more
refined definition of LM margins is expected to better guide
patients’ expectations of treatment, improve surgical planning
and cure rates, and decrease the amount of normal tissue
removed during surgery.
Although VivaScope may improve patient care and management
[4-11], there is a lack of data from the United Kingdom [3]. It
is felt that the applicability of the existing evidence to a UK
population is unclear. Relevant differences between the United
Kingdom and other countries with evidence of the impact of
VivaScope are as follows: the underlying incidence of melanoma
in different patient populations, the fact that most treatment in
United Kingdom is performed by a public health system (NHS),
there are fewer dermatologists in the United Kingdom, and most
screening in the United Kingdom occurs in primary care prior
to specialist referral. Therefore, the guidance recommended
further research to address uncertainties in the potential benefits
of using VivaScope to patients and the NHS.
The proposed diagnostic accuracy study will (1) assess the
specificity, sensitivity, and positive and negative predictive
value of VivaScope (following dermoscopy) to diagnose
melanoma using the histological assessment of the surgically
excised lesion as the gold standard and (2) assess the ability of
VivaScope to accurately delineate the pathological margins of
LM compared with that of dermoscopy alone using histological
assessment of the lateral margins taken during Mohs
micrographic surgery as the gold standard. If the outcomes of
the proposed study are in favor of VivaScope, its adoption would
potentially benefit patients and the NHS.
Objectives
The aim of this study is two-fold; the study aims (1) to assess
the efficacy of VivaScope as an additional diagnostic tool prior
to the surgical management of patients with suspected melanoma
(first cohort) and (2) to define the surgical margins before the
surgical management of LM (second cohort).
Methods
Type of Study
This is a prospective, experimental, multicenter study with a
diagnostic accuracy cohort and a margin delineation cohort.
The study design was chosen because it is pragmatic and
represents the current NHS pathway for the diagnosis of
melanoma.
Setting
For a UK study, patient recruitment for the diagnostic accuracy
cohort should occur in skin cancer screening clinics within the
NHS. Image interpretation should also be carried out at
additional reporting sites. The sites can be linked to the image
interpretation sites with VivaNet, a Web-based portal for image
viewing and reporting provided by the manufacturer of
VivaScope.
Recruitment to the margin delineation cohort must be from a
Mohs center in the United Kingdom. The involvement of
additional independent reporting clinicians for the margin
delineation protocol is not possible because the handheld
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VivaScope 3000 is used to delineate the margin using the
real-time images.
Study Population
Consecutive patients will be included if they are at least 18 years
of age and can give written informed consent.
Diagnostic Accuracy
The diagnostic accuracy cohort will include patients with
pigmented lesions suspected of being diagnosed with melanoma
and having an equivocal finding on dermoscopy or persistent
clinical suspicion (despite normal dermoscopy), who are
undergoing excision or being followed up for monitoring. In
addition, patients with equivocal lesions that are being monitored
will also be imaged but will not have a histologically confirmed
diagnosis. Such patients will be reviewed at 3 months and
followed up at 1 year. If the lesion has not been removed by 1
year, this will be used as a surrogate marker for true negatives.
Potentially, lesions considered equivocal on dermoscopy and
initially intended for monitoring, but subsequently considered
suspicious of melanoma on confocal microscopy, could be
considered for excision. It will be documented if this influenced
the decision to excise the lesion at this time. Where a patient
has more than one eligible lesion, a maximum of one lesion per
patient will be assessed. In these cases, the clinician will be
instructed to include the most suspicious lesion in the study.
Assessment will done by an experienced dermatologist.
Patients will be excluded from the diagnostic accuracy cohort
if they have a clear positive finding (melanoma) from
dermoscopy, as assessed by an experienced dermatologist or
have a clear negative finding (no melanoma) from dermoscopy,
as assessed by an experienced dermatologist, unless there is
persistent clinical suspicion. Patients who have atypical mole
syndrome or a genetic disease with high risk of melanoma (eg,
xeroderma pigmentosum), hyperkeratotic lesions, and lesions
within mucous membranes (eg, inside the mouth, very close to
the eyes, and on the genitals), where it is not possible to perform
imaging, will also be excluded.
Patients are assessed for inclusion or exclusion based on the
clinical examination of the mole (usually includes a clinical
history, unaided visual and dermoscopic assessment of the mole,
and assessment of a patient’s other moles for comparison). The
assessment by the referring clinician that a mole is equivocal is
made primarily on the basis of dermoscopy findings but other
aspects of the assessment will also influence this. The
dermoscopic assessment of the lesion being equivocal by a
referring clinician will be based on a combination of algorithmic
and intuitive approaches. This may result in a mole being
deemed equivocal despite a normal formal dermoscopic
assessment score. Because the inclusion criteria for this study
are designed to reflect the clinician’s suspicion and normal
clinical practice, the referring clinician will not be expected to
formally document a dermoscopic score, only to indicate the
reason for referral (ie, monitoring or excision). On entering the
study, the patient will be assessed via a second dermoscopy
examination by the research team. This examination will be
formally scored and the dermoscopic image photographed. The
patient will remain in the study despite the outcome of the study
dermoscopy for the reasons explained above.
Figure 1. Study procedure. NHS: National Health Service; RCM: reflectance confocal microscopy.
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The margin delineation cohort will include patients with a
confirmed histopathological diagnosis of LM (primary or
recurrent) who are undergoing Mohs surgery. Patients will be
excluded if LM melanoma is diagnosed during the Mohs
procedure.
Study Procedure
The primary study outcomes will be the diagnostic accuracy of
VivaScope for the first cohort of patients and margin agreement
between VivaScope and the final pathology report for the second
cohort of patients.
The study procedure is outlined in Figure 1.
Diagnostic Accuracy
In the diagnostic accuracy cohort, after the participant is enrolled
and provides consent, VivaScope imaging will be used as an
adjunct to clinical examination for all equivocal moles. The
clinical examination will take approximately 5 minutes with the
dermatoscope and approximately 15 minutes with VivaScope
1500 (fixed head). The investigating clinicians will assess the
moles as safe, equivocal (either monitor or excise), or suspicious.
Based on current practice, moles that are monitored are followed
up at 3 months to assess changes over time. At this appointment,
a decision is usually made to either excise the mole or discharge
the patient. Lesions considered equivocal on dermoscopy but
suspicious of melanoma on confocal microscopy may be
reclassified for excision, in which case this would be
documented.
A medical photograph, including dermoscopic images of the
lesion, will be taken prior to surgical excision or monitoring of
the lesion. To avoid potential bias, the dermoscopy score of the
lesion assessed by the research team, medical photograph, type
of clinical concern, clinical history, and patient risk factors for
melanoma will all be assessed and documented before any
histological results are available and made known to the
investigator. For patients with multiple lesions, the most
suspicious equivocal lesion will be imaged.
Margin Delineation
For the margin delineation cohort, once the participant is
enrolled and consent is obtained, relevant clinical history and
a preoperative photograph will be taken. The clinical margins
of LM will be determined by clinical and dermoscopic
examination, which will take approximately 15 minutes. A
trained professional will also examine the lesion margins with
the handheld VivaScope 3000 device, which will take
approximately 45 minutes. The aim will be to delineate the
tumor circumferentially, imaging radially outwards from the
center in 4-8 directions. Where no features of LM are seen, a
mark will be placed on the skin. A photograph of the marks will
be taken with a ruler placed on the skin for scale and with this
information, the preoperative size can be calculated via computer
software.
Prior to surgery, the margin will be delineated clinically and
then using VivaScope. These margins will both be photographed
so that any differences can be calculated. Margin assessment
may be performed during the surgical preassessment stage and
not on the day of surgery, so as not to delay surgery on the day.
For cases not delineated by both techniques on the day, the
clinical margin will be redrawn and photographed again.
Because LM grows slowly, we do not expect any differences
in the measured clinical size of LM (between the preoperative
assessment and on the day of surgery). Any differences seen
will be assumed to be attributable to variation in the measuring
technique, unless photography shows an unequivocal change
in the size and shape of LM.
All patients going through surgery will undergo slow Mohs
micrographic surgery. The margins, as assessed by visual
examination (including dermoscopy), will be used to guide the
first stage of surgery rather than the RCM-measured margin.
The first stage of slow Mohs surgery will be performed with a
2-mm margin, in addition to the clinical margin. The excised
tissue will be fixed in formalin and then sectioned and stained
using hematoxylin and eosin stains the following day. All slides
will be read by a Mohs surgeon and a histopathologist. During
each further stage of Mohs surgery, 2 mm of tissue around the
positive margin will be removed.
Once the lesion is histologically clear, the number of layers
(number of small pieces of skin removed during Mohs surgery)
and their locations (taken from photographs) can be used to
calculate the increase in size from the clinical margin. This will
be aided by the digital measurements obtained from clinical
photography to determine the surgical defect size, and this
method may account for skin tension (which is lost once the
skin is cut and changes in size and color). Therefore, for
example, if the clinical margin were correct initially, the surgical
defect size would be measured to be exactly 2 mm larger in all
directions. This same approach will be used to compare the
clinically and confocally delineated margins. The difference
between the presurgical margins previously measured using
VivaScope and the calculated margins of the surgical defect
will be calculated.
LM patients will have follow-up at 3 months and annually for
a minimum of 5 years to monitor recurrence.
Outcome Assessment and Data Collection
Diagnostic Accuracy
Clinical assessment of the lesion and confocal imaging will be
performed prior to surgical excision. It will be documented if
VivaScope imaging findings are positive, negative, or the lesion
could not be imaged (due to technical reasons). As noted
previously, it will also be documented if the imaging resulted
in an equivocal mole being reclassified as a suspicious
melanoma, affecting the decision to excise the lesion. Additional
remote clinicians will also perform an assessment independently.
These remote assessing clinicians will have access to the relevant
clinical history, dermoscopy, and clinical and confocal images.
However, they will be blinded to the histological diagnosis. The
clinicians will be asked to complete a Web-based evaluation
form that will include a description of VivaScope imaging
findings as well as a diagnostic judgment rated as positive or
negative for the presence of cancer. VivaNet, a telepathology
network for reviewing VivaScope imaging (not in real time),
will be used to assess the images remotely.
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Histopathological assessment, the reference standard for
diagnostic accuracy, will be performed by a consultant
dermatopathologist blinded to the result of RCM examination
to eliminate review bias.
Margin Delineation
For the second cohort, the size of the margins will be recorded
for VivaScope measurement as well as for slow Mohs surgery.
The calculation of the surgical defect will also be recorded. The
outcome measure will be the difference between the predicted
margins using VivaScope and the Mohs size of the defect in the
same patient. Thus, we are comparing the confocal microscope
margin with the clinically predicted margin in each patient.
Additional data will be collected on the time it takes to obtain
test results, interobserver variability in the interpretation of
VivaScope imaging, imaging failure rate, morbidity associated
with biopsy or surgery, and adverse events from biopsy or
surgery. The clinician administering the tests will record results
on data collection forms by hand.
Sample Size
Diagnostic Accuracy
Based on a systematic review and meta-analysis, the expected
VivaScope specificity compared with the gold standard of
histopathology is 90% [4], but for this calculation, a conservative
estimate of 80% was used. A sample of 100 (true negatives)
would provide a 95% CI for this VivaScope specificity of
70.8%-87.3%. This would allow us to conclude that the true
specificity is >70%.
Assuming a disease prevalence of 20% (among this patient
group who are equivocal on dermoscopy), 80% of patients tested
will be true negatives on biopsy or after 1 year of monitoring
without excision. Therefore, to achieve 100 true negatives, 125
patients will be included in this study (ie, tested by VivaScope,
dermoscopy, and biopsy or monitoring).
Margin Delineation
The actual surgical margins achieved (which will have been
guided by dermoscopy) will be compared with the hypothetical
margins indicated by VivaScope for each patient. The paired
mean difference in margins between surgery and VivaScope
will be compared using the paired t test. Assuming a moderate
standardized effect size of 0.4 and 90% power, a sample of 68
patients is required (PASS v15.0 software; NCSS, Utah, USA).
A standardized effect size has been used owing to the absence




We will calculate the specificity of VivaScope (95% CI) in
predicting true negatives, as defined by histopathology or 1 year
of monitoring without excision of the lesion. Specificity is
calculated as negative VivaScope results divided by true
negatives. The sensitivity of VivaScope will also be calculated,
as positive VivaScope results in the numerator divided by true
positives in the denominator, to check that the expected gain in
specificity is not at the cost of sensitivity. True positives will
be defined by the histopathology of excised lesions, including
those excised during the 1-year monitoring period. Positive and
negative predictive values will also be calculated.
We will compute kappa statistics to calculate the interobserver
agreement. The conventional classification on the basis of kappa
statistics from almost perfect agreement (>.81), moderate
agreement (.41-.60), and slight to poor agreement (<.20) will
be used [12].
Margin Delineation
McNemar’s test will be used to compare the frequency of
surgery documenting clear margins for VivaScope compared
with clinical examination with dermoscopy, and the paired t
test will be used to compare the mean margins.
Ethics and Governance
Prior to initiating this study, the protocol would need Health
Research Authority (HRA) approval, wherein HRA staff and
an independent Research Ethics Committee will assess
governance and ethical compliance for projects led from the
NHS in the United Kingdom. Patients in the diagnostic accuracy
cohort will be approached after their initial appointment if they
are eligible to participate, and LM patients will be approached
during their first consultation. Patients will be given information
about the study and asked whether they would like to participate.
If the patient is interested, the clinician will explain the aims,
methods, and anticipated benefits of the study. The patient will
be able to ask any questions or voice any concerns about the
study prior to giving written consent. The patient will be able
to withdraw from the study at any time.
The investigator has a responsibility to ensure that patient
anonymity is protected and maintained. The investigator will
ensure that identities are protected from any unauthorized
parties. Information regarding study patients will be kept
confidential and managed in accordance with the General Data
Protection Regulation, NHS Caldicott Guardian requirements,
The Research Governance Framework for Health and Social
Care, and Research Ethics Committee approval. A
pseudoanonymized identifier will be necessary for the margin
delineation cohort.
Data will stay in the NHS and within the University sponsor’s
computer system under normal arrangements for patient
confidentiality and will include encryption and locked storage
of all patient data. The chief investigator, principal investigator,
and authorized researchers on the study team will have access
to the information for purposes of data monitoring, validation,
and analyses.
Results
Funding for this proposed research is being secured.
Discussion
Strengths
This study aims to address the uncertainties identified in NICE
DG19 by carrying out a prospective diagnostic accuracy study
in the United Kingdom. NICE DG19 states that additional
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evidence should be collected relating to the use of VivaScope
to inform decisions as to whether to biopsy and excise suspicious
skin lesions as well as to define margins in LM patients.
The implementation of VivaScope in clinical practice has the
potential to improve the accuracy of the diagnostic process.
VivaScope is noninvasive and would reduce the number of
surgical interventions. It would also lead to a better patient
experience, particularly lessening patient anxiety due to
uncertainty while waiting for a diagnosis. In the margin
delineation cohort, VivaScope could minimize the amount of
normal tissue excised unnecessarily and reduce the duration
and number of stages of the Mohs surgery.
The outcomes captured in the study aim to address the
recommendations from NICE DG19, which prompted the
development of this protocol. NICE will update its guidance
for clinical use if substantive evidence is generated as part of
this study on VivaScope. NICE guidance would give a strong
steer to the national and international adoption of VivaScope.
Thus, this study would have a high impact.
Challenges
Extending the study to multiple sites may be a better
demonstration of applicability to the NHS. A major current
drawback to this is the lack of suitable clinical centers in the
United Kingdom that currently have the expertise in using
VivaScope. In practice, the variable levels of expertise and cost
of training could be a barrier for the adoption of the device.
There is potential to find greater benefit in clinics with a large
cohort of patients being monitored for high-risk moles but this
would apply to only a limited number of services in the United
Kingdom, as opposed to every hospital that has referrals for
skin cancer.
Future Directions
This study should influence a wider uptake of VivaScope for
the diagnosis of pigmented lesions at the bedside, reducing
unnecessary excisions. The results from this study should also
increase the use of VivaScope for margin delineation in LM
patients in the United Kingdom. As the technique becomes more
established, it will be useful to conduct further research on the
use of VivaScope to replace confirmatory biopsies for basal cell
carcinomas prior to definitive treatment.
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